Biomarkers and pulmonary stenosisKan and her associates 1 applied the techniques described by Dotter, Grüntzig and their associates to dilate stenotic pulmonary valve in the early 1980s. This technique was rapidly adopted by many cardiologists as reviewed elsewhere 2,3 and balloon pulmonary valvuloplasty (BPV) became the treatment of choice for relief of pulmonary valve stenosis 4,5 and indeed, it replaced surgical pulmonary valvotomy.Immediate, intermediate-term, and long-term follow-up results of BPV were well documented in the literature. [6][7][8][9][10] The BPV procedure was also extended to the fetuses, 11 neonates, 12 and adults, 13 successfully.Initially, cardiac catheterization was used to assess the follow-up results of BPV. 4,14 Following the demonstration of the efficacy of echo-Doppler studies in quantifying the residual gradients, [14][15][16] echo-Doppler studies were used almost exclusively by most investigators in the assessment of the results of BPV at follow-up. Peak Doppler flow velocity is used to calculate peak instantaneous Doppler gradient using modified Bernoulli equation (∆P = 4V 2 -where ∆P is pressure gradient and V is peak Doppler flow velocity across the pulmonary valve). However, the peak instantaneous gradient overestimates the true catheterization-derived gradient because of pressure recovery phenomenon 17 ; the calculated gradients should be adjusted to account for pressure recovery. Although not widely reported, electrocardiogram (ECG) is also useful in the evaluation of follow-up results of BPV. 18